@sands_jacob 联合 Dellphi305——tarlatamab 联合 durvalumab 对比 durvalumab 治疗小细胞肺癌——总生存期近乎翻倍，CRS 可管理，且可接受门诊治疗。为小细胞肺癌喝彩！@nejm 今日同步发表。
@oncoalert @myESMO #ESMO26
32 浏览 · 2 赞 · 2 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com